Draft RPP: New Vaccine Platforms (NVP)

Solicitation Description

DRAFT – FOR ADVANCE NOTICE AND TEAMING PURPOSES ONLY.

This Draft Request for Project Proposals (RPP) is being released for informational purposes to provide prospective offerors with advance notice of a potential upcoming solicitation and to facilitate teaming and partnership discussions.

The objective of the NVP Program is to identify new vaccine platforms for the BARDA MCM portfolio and advance them through an initial manufacturing and nonclinical capability demonstration to identify technologies that are (1) safe; (2) effective across multiple infectious disease threats from different pathogen families; and (3) support development and manufacturing that would enable an effective response during an emerging national health security incident.

Advancing vaccine platforms that are safe and adaptable across multiple infectious disease threats, and enable streamlined development and manufacturing will help ensure the U.S. MCM portfolio is optimally positioned to respond efficiently and effectively to national health security incidents.

Feedback and Questions
As part of the draft RPP release, BARDA is requesting feedback and questions related to release. Please submit to ATI ([email protected]) by September 4, 2026 by 12pm ET.

Proposals are not being solicited or accepted at this time. This Draft RPP does not constitute a formal solicitation, request for proposals, or commitment to make an award. All requirements, dates, technical content, evaluation criteria, and other information contained herein are preliminary and subject to change prior to release of the final RPP.

Interested organizations should not submit proposals in response to this Draft RPP. Instructions and deadlines for proposal submission will be provided with the final RPP, if and when released.